{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:20:28Z","timestamp":1787631628255,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11912-018-0708-8","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T10:22:12Z","timestamp":1529576532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Tyrosine Kinase Inhibitor-Induced Hypertension"],"prefix":"10.1007","volume":"20","author":[{"given":"Megha","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Thareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Akhondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"708_CR1","unstructured":"Whelton PK, Carey RM, Aronow WS et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2017."},{"key":"708_CR2","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 125 million people. Lancet. 2014;383:1899\u2013911.","journal-title":"Lancet"},{"key":"708_CR3","doi-asserted-by":"publisher","first-page":"e1000058","DOI":"10.1371\/journal.pmed.1000058","volume":"6","author":"G Danaei","year":"2009","unstructured":"Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJL, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6:e1000058.","journal-title":"PLoS Med"},{"key":"708_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11906-007-0058-7","volume":"9","author":"M Jain","year":"2007","unstructured":"Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep. 2007;9:320\u20138.","journal-title":"Curr Hypertens Rep"},{"key":"708_CR5","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","volume":"26","author":"H Izzedine","year":"2015","unstructured":"Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol. 2015;26:1128\u201333.","journal-title":"Ann Oncol"},{"key":"708_CR6","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) V 3.0. ."},{"key":"708_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jnci\/djq091","volume":"102","author":"ML Maitland","year":"2010","unstructured":"Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596\u2013604.","journal-title":"J Natl Cancer Inst"},{"key":"708_CR8","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol. 2009;53:2231\u201347.","journal-title":"J Am Coll Cardiol"},{"key":"708_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med. 2003;349:427\u201334.","journal-title":"N Engl J Med"},{"key":"708_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00228-010-0815-4","volume":"66","author":"MM An","year":"2010","unstructured":"An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 2010;66:813\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"708_CR11","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of Cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol. 2017;70:2552\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"708_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/02841860802314720","volume":"48","author":"X Zhu","year":"2009","unstructured":"Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48:9\u201317.","journal-title":"Acta Oncol"},{"key":"708_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc072330","volume":"358","author":"M Azizi","year":"2008","unstructured":"Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358:95\u20137.","journal-title":"N Engl J Med"},{"key":"708_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","volume":"9","author":"S Wu","year":"2008","unstructured":"Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:117\u201323.","journal-title":"Lancet Oncol"},{"key":"708_CR15","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","volume":"15","author":"ML Maitland","year":"2009","unstructured":"Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;15:6250\u20137.","journal-title":"Clin Cancer Res"},{"key":"708_CR16","doi-asserted-by":"crossref","unstructured":"Pinkhas DHTSS. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardio-Oncology. 2017;3","DOI":"10.1186\/s40959-017-0024-8"},{"key":"708_CR17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7555\/JBR.32.20170080","volume":"32","author":"F Qin","year":"2018","unstructured":"Qin F, Yu H, Xu CR, Chen HH, Bai JL. Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis. J Biomed Res. 2018;32:30\u20138.","journal-title":"J Biomed Res"},{"key":"708_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2215\/CJN.08111109","volume":"5","author":"ES Robinson","year":"2010","unstructured":"Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010;5:477\u201383.","journal-title":"Clin J Am Soc Nephrol"},{"key":"708_CR19","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210\u20138.","journal-title":"J Clin Oncol"},{"key":"708_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123\u20139.","journal-title":"Blood"},{"key":"708_CR21","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"708_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494\u2013500.","journal-title":"Blood"},{"key":"708_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1101\/gad.13.9.1055","volume":"13","author":"NW Gale","year":"1999","unstructured":"Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 1999;13:1055\u201366.","journal-title":"Genes Dev"},{"key":"708_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrc2353","volume":"8","author":"CJ Avraamides","year":"2008","unstructured":"Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8:604\u201317.","journal-title":"Nat Rev Cancer"},{"key":"708_CR25","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrc2444","volume":"8","author":"C Murdoch","year":"2008","unstructured":"Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618\u201331.","journal-title":"Nat Rev Cancer"},{"key":"708_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/scbi.1998.0091","volume":"9","author":"T Veikkola","year":"1999","unstructured":"Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 1999;9:211\u201320.","journal-title":"Semin Cancer Biol"},{"key":"708_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ijc.11068","volume":"105","author":"T Kuwai","year":"2003","unstructured":"Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E, et al. Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer. 2003;105:176\u201381.","journal-title":"Int J Cancer"},{"key":"708_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669\u201376.","journal-title":"Nat Med"},{"key":"708_CR29","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011\u201327.","journal-title":"J Clin Oncol"},{"key":"708_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60\u20135.","journal-title":"J Clin Oncol"},{"key":"708_CR31","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1158\/1078-0432.CCR-07-0847","volume":"13","author":"HM Verheul","year":"2007","unstructured":"Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007;13:5341\u20137.","journal-title":"Clin Cancer Res"},{"key":"708_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58\u201362.","journal-title":"Science"},{"key":"708_CR33","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788\u201395.","journal-title":"Br J Cancer"},{"key":"708_CR34","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","volume":"54","author":"CS Facemire","year":"2009","unstructured":"Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652\u20138.","journal-title":"Hypertension"},{"key":"708_CR35","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1345\/aph.1H244","volume":"40","author":"M Dincer","year":"2006","unstructured":"Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother. 2006;40:2278\u20139.","journal-title":"Ann Pharmacother"},{"key":"708_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cardiores.2007.06.004","volume":"76","author":"F Bohm","year":"2007","unstructured":"Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007;76:8\u201318.","journal-title":"Cardiovasc Res"},{"key":"708_CR37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","volume":"56","author":"MH Kappers","year":"2010","unstructured":"Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56:675\u201381.","journal-title":"Hypertension"},{"key":"708_CR38","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ajh.2012.97","volume":"25","author":"N Jesus-Gonzalez de","year":"2012","unstructured":"de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M, Heinrich MC, Tap W, et al. Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens. 2012;25:1118\u201323.","journal-title":"Am J Hypertens"},{"key":"708_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","volume":"59","author":"MH Kappers","year":"2012","unstructured":"Kappers MH, de Beer VJ, Zhou Z, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2012;59:151\u20137.","journal-title":"Hypertension"},{"key":"708_CR40","first-page":"H547","volume":"290","author":"F Baffert","year":"2006","unstructured":"Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Phys Heart Circ Phys. 2006;290:H547\u201359.","journal-title":"Am J Phys Heart Circ Phys"},{"key":"708_CR41","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/annonc\/mdm550","volume":"19","author":"JJ Mourad","year":"2008","unstructured":"Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19:927\u201334.","journal-title":"Ann Oncol"},{"key":"708_CR42","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1681\/ASN.2007020255","volume":"18","author":"IE Stillman","year":"2007","unstructured":"Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol. 2007;18:2281\u20134.","journal-title":"J Am Soc Nephrol"},{"key":"708_CR43","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnci\/djm311","volume":"100","author":"TV Patel","year":"2008","unstructured":"Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008;100:282\u20134.","journal-title":"J Natl Cancer Inst"},{"key":"708_CR44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186\u201393.","journal-title":"Am J Kidney Dis"},{"key":"708_CR45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"\u2022\u2022 Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763\u201373. This article is the largest study to highlight that hypertension can be used as a biomarker for VSP inhibition success in treating a cancer. It lends to further research questions of treatment success, failures, and possible relation to dosing.","journal-title":"J Natl Cancer Inst"},{"key":"708_CR46","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011\u20139.","journal-title":"Lancet"},{"key":"708_CR47","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","volume":"26","author":"M Schmidinger","year":"2008","unstructured":"Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204\u201312.","journal-title":"J Clin Oncol"},{"key":"708_CR48","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. Jama. 2004;291:2441\u20137.","journal-title":"Jama"},{"key":"708_CR49","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","volume":"60","author":"N Jesus-Gonzalez de","year":"2012","unstructured":"de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension. 2012;60:607\u201315.","journal-title":"Hypertension"},{"key":"708_CR50","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","volume":"21","author":"RR McKay","year":"2015","unstructured":"\u2022\u2022 McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21:2471\u20139. Largest meta-analysis that shows an association with use of a specific anti-hypertensive medication and improvement in overall survival during therapy with a VSP inhibitor. Validates the importance of treatment of hypertension and modifies how future trials of TKI inhibitors may be run.","journal-title":"Clin Cancer Res"},{"key":"708_CR51","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","volume":"30","author":"O Mir","year":"2012","unstructured":"Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S, et al. Treatment of bevacizumab-induced hypertension by amlodipine. Investig New Drugs. 2012;30:702\u20137.","journal-title":"Investig New Drugs"},{"key":"708_CR52","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1291\/hypres.28.147","volume":"28","author":"S Miura","year":"2005","unstructured":"Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor\/fetal liver kinase-1\/NO pathway. Hypertens Res. 2005;28:147\u201353.","journal-title":"Hypertens Res"},{"key":"708_CR53","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-07-4783","volume":"14","author":"JO Curwen","year":"2008","unstructured":"Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res. 2008;14:3124\u201331.","journal-title":"Clin Cancer Res"},{"key":"708_CR54","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","volume":"27","author":"MH Langenberg","year":"2009","unstructured":"Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27:6152\u20139.","journal-title":"J Clin Oncol"},{"key":"708_CR55","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","volume":"124","author":"B Nazer","year":"2011","unstructured":"Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011;124:1687\u201391.","journal-title":"Circulation"},{"key":"708_CR56","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/annonc\/mdm205","volume":"18","author":"LY Dirix","year":"2007","unstructured":"Dirix LY, Maes H, Sweldens C. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol. 2007;18:1121\u20132.","journal-title":"Ann Oncol"},{"key":"708_CR57","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1161\/01.CIR.0000014928.45119.73","volume":"105","author":"JP Cooke","year":"2002","unstructured":"Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation. 2002;105:2133\u20135.","journal-title":"Circulation"},{"key":"708_CR58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/2050-6511-14-48","volume":"14","author":"RP Mason","year":"2013","unstructured":"Mason RP, Jacob RF, Corbalan JJ, Szczesny D, Matysiak K, Malinski T. The favorable kinetics and balance of nebivolol-stimulated nitric oxide and peroxynitrite release in human endothelial cells. BMC Pharmacol Toxicol. 2013;14:48.","journal-title":"BMC Pharmacol Toxicol"},{"key":"708_CR59","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/bjc.2013.205","volume":"108","author":"E Pasquier","year":"2013","unstructured":"Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, et al. Beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer. 2013;108:2485\u201394.","journal-title":"Br J Cancer"},{"key":"708_CR60","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/HJH.0b013e32835c1d1b","volume":"31","author":"S Lankhorst","year":"2013","unstructured":"Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens. 2013;31:444\u201354. discussion 454","journal-title":"J Hypertens"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-018-0708-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0708-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0708-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T04:42:04Z","timestamp":1693716124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-018-0708-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s11912-018-0708-8","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"21 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Megha Agarwal, Nidhi Thareja, Melody Benjamin, Andre Akhondi, and George D. Mitchell declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"65"}}